Shares of Gene Logic Inc. (Nasdaq:GLGC) are edging up in pre-market trading this morning after the pharmaceutical company announced that it will collaborate with the U.S. Food and Drug Administration (FDA) to share quality control methods and metrics to better understand dissimilar genomic data sent as part of regulatory submissions.

The collaboration is part of the FDA's “Critical Path Initiative,” an effort to facilitate the use of new scientific and technical methods, such as computer-based predictive models, to improve the predictability and efficiency of drug development from the lab to the shelf.

Shares of Gene Logic edged up $0.03, or 2.34%, to $1.27 in pre-market trading.

For access to the full article, you must be a registered member - it's FREE.